 Invokana canagliflozin: Additional Phase III data - BioCentury.comHome Week in Review Clinical Results Invokana canagliflozin: Additional Phase III dataInvokana canagliflozin: Additional Phase III dataMitsubishi Tanabe Pharma Corp. Tokyo:4508; Osaka:4508, Osaka, JapanJohnson Johnson NYSE:JNJ, New Brunswick, N.J.OrganizationsJohnson JohnsonMitsubishi Tanabe Pharma Corp.ProductsInvokanaJNJ-28431754TA-7284Molecular TargetsSodium-glucose cotransporter 2 SGLT2 